{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:26:13Z","timestamp":1773300373430,"version":"3.50.1"},"reference-count":48,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":2905,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Metformin has been associated with a reduction in breast cancer risk and may improve survival after cancer through direct and indirect tumor-suppressing mechanisms. The purpose of this study was to evaluate the effect of metformin therapy on survival in women with breast cancer using methods that accounted for the duration of treatment with glucose-lowering therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This population-based study, using Ontario health care databases, recruited women aged 66 years or older diagnosed with diabetes and breast cancer between 1 April 1997 and 31 March 2008. Using Cox regression analyses, we explored the association between cumulative duration of past metformin use and all-cause and breast cancer\u2013specific mortality. We modeled cumulative duration of past metformin use as a time-varying exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of 2,361 breast cancer patients identified, mean (\u00b1 SD) age at cancer diagnosis was 77.4 \u00b1 6.3 years, and mean follow-up was 4.5 \u00b1 3.0 years. There were 1,101 deaths(46.6%), among which 386 (16.3%) were breast cancer\u2013specific deaths. No significant association was found between cumulative duration of past metformin use and all-cause mortality (adjusted hazard ratio 0.97 [95% CI 0.92\u20131.02]) or breast cancer\u2013specific mortality (0.91 [0.81\u20131.03]) per additional year of cumulative use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Our findings failed to show an association between improved survival and increased cumulative metformin duration in older breast cancer patients who had recent-onset diabetes. Further research is needed to clarify this association, accounting for effects of cancer stage and BMI in younger populations or those with differing stages of diabetes as well as in nondiabetic populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc12-2535","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T12:18:02Z","timestamp":1367410682000},"page":"3018-3026","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":91,"title":["Association Between Metformin Therapy and Mortality After Breast Cancer"],"prefix":"10.2337","volume":"36","author":[{"given":"Iliana C.","family":"Lega","sequence":"first","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"The Institute for Evaluative and Clinical Sciences, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gruneir","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"The Institute for Evaluative and Clinical Sciences, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela J.","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula A.","family":"Rochon","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"The Institute for Evaluative and Clinical Sciences, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine L.","family":"Lipscombe","sequence":"additional","affiliation":[{"name":"Women\u2019s College Research Institute, Women\u2019s College Hospital, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"The Institute for Evaluative and Clinical Sciences, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2013,9,14]]},"reference":[{"key":"2022031221291473400_B1","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"key":"2022031221291473400_B2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1470-2045(05)01736-5","article-title":"Diabetes mellitus and breast cancer","volume":"6","author":"Wolf","year":"2005","journal-title":"Lancet Oncol"},{"key":"2022031221291473400_B3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1254116","article-title":"Breast cancer and diabetes mellitus","volume":"118","author":"Schott","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2022031221291473400_B4","first-page":"39","article-title":"Update on the Canadian Diabetes Association 2008 clinical practice guidelines","volume":"55","author":"Bhattacharyya","year":"2009","journal-title":"Can Fam Physician"},{"key":"2022031221291473400_B5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc12-s004","article-title":"Executive summary: Standards of medical care in diabetes\u20142012","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221291473400_B6","doi-asserted-by":"crossref","first-page":"e33411","DOI":"10.1371\/journal.pone.0033411","article-title":"Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis","volume":"7","author":"Noto","year":"2012","journal-title":"PLoS ONE"},{"key":"2022031221291473400_B7","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"2022031221291473400_B8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-012-2170-x","article-title":"Metformin and breast cancer risk: a meta-analysis and critical literature review","volume":"135","author":"Col","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022031221291473400_B9","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022031221291473400_B10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10549-011-1612-1","article-title":"Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial","volume":"128","author":"Hadad","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2022031221291473400_B11"},{"key":"2022031221291473400_B12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10549-012-2223-1","article-title":"Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study","volume":"135","author":"Niraula","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022031221291473400_B13"},{"key":"2022031221291473400_B14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cncr.26439","article-title":"Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer","volume":"118","author":"Bayraktar","year":"2012","journal-title":"Cancer"},{"key":"2022031221291473400_B15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","article-title":"Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm","volume":"25","author":"Hux","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031221291473400_B16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","article-title":"An application of capture-recapture methods to the estimation of completeness of cancer registration","volume":"41","author":"Robles","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"2022031221291473400_B17","first-page":"16","article-title":"Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients","volume":"30","author":"Brenner","year":"2009","journal-title":"Chronic Dis Can"},{"key":"2022031221291473400_B18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2022031221291473400_B19"},{"key":"2022031221291473400_B20"},{"key":"2022031221291473400_B21"},{"key":"2022031221291473400_B22"},{"key":"2022031221291473400_B23","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.ejca.2008.09.013","article-title":"Her2-positive breast cancer: herceptin and beyond","volume":"44","author":"Dean-Colomb","year":"2008","journal-title":"Eur J Cancer"},{"key":"2022031221291473400_B24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/dc11-1313","article-title":"Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival","volume":"35","author":"Currie","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221291473400_B25"},{"key":"2022031221291473400_B26"},{"key":"2022031221291473400_B27"},{"key":"2022031221291473400_B28"},{"key":"2022031221291473400_B29"},{"key":"2022031221291473400_B30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00125-012-2526-0","article-title":"Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer","volume":"55","author":"Renehan","year":"2012","journal-title":"Diabetologia"},{"key":"2022031221291473400_B31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2011.08.002","article-title":"Administrative database research has unique characteristics that can risk biased results","volume":"65","author":"van Walraven","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"2022031221291473400_B32","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1002\/sim.3437","article-title":"The impact of time-dependent bias in proportional hazards modelling","volume":"27","author":"Beyersmann","year":"2008","journal-title":"Stat Med"},{"key":"2022031221291473400_B33","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221291473400_B34","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"key":"2022031221291473400_B35","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res"},{"key":"2022031221291473400_B36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/er.2008-0047","article-title":"Insulin receptor isoforms and insulin receptor\/insulin-like growth factor receptor hybrids in physiology and disease","volume":"30","author":"Belfiore","year":"2009","journal-title":"Endocr Rev"},{"key":"2022031221291473400_B37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13813450801969715","article-title":"The role of insulin receptors and IGF-I receptors in cancer and other diseases","volume":"114","author":"Frasca","year":"2008","journal-title":"Arch Physiol Biochem"},{"key":"2022031221291473400_B38","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res"},{"key":"2022031221291473400_B39","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/156652410792630625","article-title":"Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells","volume":"10","author":"Vazquez-Martin","year":"2010","journal-title":"Curr Mol Med"},{"key":"2022031221291473400_B40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exger.2005.07.007","article-title":"Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2\/neu transgenic mice","volume":"40","author":"Anisimov","year":"2005","journal-title":"Exp Gerontol"},{"key":"2022031221291473400_B41"},{"key":"2022031221291473400_B42"},{"key":"2022031221291473400_B43","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.285.7.885","article-title":"Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older","volume":"285","author":"Yancik","year":"2001","journal-title":"JAMA"},{"key":"2022031221291473400_B44"},{"key":"2022031221291473400_B45","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","article-title":"Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis","volume":"134","author":"Niraula","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022031221291473400_B46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","article-title":"Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis","volume":"123","author":"Protani","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2022031221291473400_B47"},{"key":"2022031221291473400_B48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-010-1224-1","article-title":"Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents","volume":"126","author":"Goodwin","year":"2011","journal-title":"Breast Cancer Res Treat"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/10\/3018\/616401\/3018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/10\/3018\/616401\/3018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:43:29Z","timestamp":1647128609000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/10\/3018\/30372\/Association-Between-Metformin-Therapy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,14]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,14]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-2535","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,14]]}}}